X Forns

Summary

Country: Spain

Publications

  1. ncbi request reprint The challenge of developing a vaccine against hepatitis C virus
    Xavier Forns
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Villaroel 170, Barcelona 08036, Spain
    J Hepatol 37:684-95. 2002
  2. ncbi request reprint HCV virological assessment
    Xavier Forns
    Liver Unit, Hospital Clinic, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 44:S35-9. 2006
  3. ncbi request reprint Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
    Xavier Forns
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Catalonia, Spain
    Hepatology 36:986-92. 2002
  4. ncbi request reprint [Treatment of chronic hepatitis C in cirrhosis of the liver]
    X Forns
    Servicio de Hepatología Institut de Malaties Digestives Hospital Clínic Barcelona Spain
    Gastroenterol Hepatol 25:356-9. 2002
  5. ncbi request reprint Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center
    X Forns
    Department of Medicine, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, Universitat de Barcelona, Catalonia, Spain
    J Hepatol 35:265-71. 2001
  6. ncbi request reprint Nosocomial transmission of HCV in the liver unit of a tertiary care center
    Xavier Forns
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Hepatology 41:115-22. 2005
  7. ncbi request reprint Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface
    X Forns
    Hepatitis Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Virology 274:75-85. 2000
  8. ncbi request reprint Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation
    Xavier Forns
    Liver Unit, Hospital Clinic, Institut de Malalties Digestives, IDIBAPS, Escala 7, 3 pis, Villarroel 170, Barcelona 08036, Spain
    J Hepatol 39:389-96. 2003
  9. ncbi request reprint The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
    J C Saiz
    Hospital Clinic, Department of Medicine, Facultad de Medicina, Universidad de Barcelona, Spain
    J Infect Dis 177:839-47. 1998
  10. ncbi request reprint High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis
    M Gimenez-Barcons
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    Hepatology 34:158-67. 2001

Detail Information

Publications65

  1. ncbi request reprint The challenge of developing a vaccine against hepatitis C virus
    Xavier Forns
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Villaroel 170, Barcelona 08036, Spain
    J Hepatol 37:684-95. 2002
  2. ncbi request reprint HCV virological assessment
    Xavier Forns
    Liver Unit, Hospital Clinic, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 44:S35-9. 2006
    ..Due to the higher viral load of co-infected patients compared to HCV mono-infected individuals, those assays with a wide dynamic range seem more appropriate to monitor viral load during treatment...
  3. ncbi request reprint Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
    Xavier Forns
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Catalonia, Spain
    Hepatology 36:986-92. 2002
    ..In conclusion, a combination of easily accessible variables accurately predicts the absence of significant fibrosis and might render liver biopsy unnecessary in more than one third of patients with chronic hepatitis C...
  4. ncbi request reprint [Treatment of chronic hepatitis C in cirrhosis of the liver]
    X Forns
    Servicio de Hepatología Institut de Malaties Digestives Hospital Clínic Barcelona Spain
    Gastroenterol Hepatol 25:356-9. 2002
  5. ncbi request reprint Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center
    X Forns
    Department of Medicine, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, Universitat de Barcelona, Catalonia, Spain
    J Hepatol 35:265-71. 2001
    ..The natural history of chronic hepatitis C (HCV) is not completely understood. This study was aimed to evaluate the long-term outcome of the disease over a prolonged period of time and to identify factors associated with progression...
  6. ncbi request reprint Nosocomial transmission of HCV in the liver unit of a tertiary care center
    Xavier Forns
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Hepatology 41:115-22. 2005
    ..Continuous reinforcement of universal prevention measures and, when possible, isolation of patients at higher risk might further reduce nosocomial HCV transmission...
  7. ncbi request reprint Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface
    X Forns
    Hepatitis Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Virology 274:75-85. 2000
    ....
  8. ncbi request reprint Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation
    Xavier Forns
    Liver Unit, Hospital Clinic, Institut de Malalties Digestives, IDIBAPS, Escala 7, 3 pis, Villarroel 170, Barcelona 08036, Spain
    J Hepatol 39:389-96. 2003
    ..One of the possible strategies to prevent HCV infection recurrence is to eradicate HCV before LT...
  9. ncbi request reprint The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
    J C Saiz
    Hospital Clinic, Department of Medicine, Facultad de Medicina, Universidad de Barcelona, Spain
    J Infect Dis 177:839-47. 1998
    ..In conclusion, low virus load and mutant NS5A-ISDR phenotype are closely associated with long-term response to interferon in HCV genotype 1b- but probably not in 3a-infected patients...
  10. ncbi request reprint High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis
    M Gimenez-Barcons
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    Hepatology 34:158-67. 2001
    ..Therefore, a mutated HCV-PKR-bd phenotype is very common in cirrhotic patients with hepatocellular carcinoma...
  11. doi request reprint Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation
    M Coto-Llerena
    Liver Unit, CIBERehd, IDIBAPS, Barcelona, Spain
    Am J Transplant 11:1051-7. 2011
    ..Interestingly, donor genotype also seems to influence the response pattern, especially in recipients who have a favorable IL28B genotype...
  12. ncbi request reprint Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation
    A Massaguer
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Ciberehd and Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Am J Transplant 7:2172-9. 2007
    ..These observations highlight the complex interplay between viral evolution and clinical outcomes in the LT setting...
  13. ncbi request reprint Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection
    A Feliu
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    J Viral Hepat 13:544-51. 2006
    ..In conclusion, in HCV-infected patients undergoing LT, the pattern of response to antiviral treatment may change after transplantation, and this possibility needs to be incorporated in clinical practice...
  14. doi request reprint Hepatitis C virus compartmentalization and infection recurrence after liver transplantation
    S Ramirez
    Liver Unit Institut de Malalties Digestives, CIBERehd, IDIBAPS and University of Barcelona, Barcelona, Spain
    Am J Transplant 9:1591-601. 2009
    ..Our study shows that a significant proportion of HCV-infected cirrhotic patients exhibit compartmentalization. Viral variants originating within the liver appear to be the main cause of HCV recurrence after LT...
  15. ncbi request reprint Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C
    F Puig-Basagoiti
    Liver Unit, Institut de Malalties Digestives, IDIBAPS, Department de Medicina, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain
    J Med Virol 65:35-44. 2001
    ..No relationship between these viral features and response to therapy was disclosed in patients infected with HCV-3a...
  16. doi request reprint Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C
    S M Martinez
    Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Aliment Pharmacol Ther 33:138-48. 2011
    ..Liver biopsy is the reference standard to assess liver fibrosis in chronic hepatitis C...
  17. doi request reprint Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting
    J Dragun
    Liver Unit, Hospital Clinic, IDIBAPS, CIBERehd and University of Barcelona, Barcelona, Spain
    Am J Transplant 11:767-74. 2011
    ..015). These data suggest that HCV adaptation via selection of the best-fitted variants may account for early viral kinetics following LT...
  18. doi request reprint Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Paul Y Kwo
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Lancet 376:705-16. 2010
    ..We tested the efficacy of boceprevir, an NS3 hepatitis C virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin...
  19. ncbi request reprint Hepatitis C virus envelope protein E2 binds to CD81 of tamarins
    T Allander
    Hepatitis Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0740, USA
    Virology 277:358-67. 2000
    ..Thus, the HCV E2 interaction with CD81 is not limited to humans and chimpanzees and does not predict susceptibility to HCV infection...
  20. ncbi request reprint Studies of hepatitis C virus in chimpanzees and their importance for vaccine development
    J Bukh
    Hepatitis Viruses and Molecular Hepatitis Sections, Laboratory of Infectious Diseases, NIAID, National Institutes of Health, Bethesda, Md 20892 0740, USA
    Intervirology 44:132-42. 2001
    ..The vaccine trials performed in chimpanzees to date all have tested the efficacy of immunizations with various forms of the envelope proteins of HCV...
  21. ncbi request reprint Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study
    José A Carrión
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Ciberehd and IDIBAPS, University of Barcelona, Barcelona, Spain
    Gastroenterology 132:1746-56. 2007
    ..Recurrence of hepatitis C virus (HCV) infection is a relevant problem of liver transplantation programs. We evaluated the effect of antiviral therapy on disease progression in 81 HCV-infected liver transplantation recipients...
  22. doi request reprint Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry)
    Manuel Ramos-Casals
    Laboratory of Autoimmune Diseases Josep Font, Department of Autoimmune Diseases, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, 08036 Barcelona, Spain
    J Rheumatol 36:1442-8. 2009
    ..To describe the clinical and immunologic characteristics of a large series of patients with systemic autoimmune diseases (SAD) associated with chronic hepatitis C virus (HCV) infection...
  23. doi request reprint Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation
    José A Carrión
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, CIBERehd, Barcelona, Spain
    Gastroenterology 138:147-58.e1. 2010
    ..This study evaluated whether serum fibrosis markers can predict hepatitis C recurrence during the first year after liver transplantation...
  24. ncbi request reprint Hospital admission is a relevant source of hepatitis C virus acquisition in Spain
    Eva Martinez-Bauer
    Liver Unit, Hospital Clinic de Barcelona, IDIBAPS, Ciber de Enfermedades Hepaticas y Digestivas, CIBERehd, Spain
    J Hepatol 48:20-7. 2008
    ..The aim of this study was to investigate the current relevance of nosocomial HCV infection...
  25. ncbi request reprint Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection
    M Ramos-Casals
    Department of Autoimmune Diseases, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, Hospital Clinic, Barcelona, Spain
    J Viral Hepat 14:736-42. 2007
    ..Associated HIV infection significantly attenuated the clinical and immunological expression of cryoglobulinaemia, except in coinfected patients with high viral loads for the two viruses...
  26. doi request reprint A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
    I M Jacobson
    Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA
    J Viral Hepat 19:1-26. 2012
    ..This practical guide will serve as a valuable resource for clinicians embarking on the new treatment paradigm of boceprevir or telaprevir in combination with peginterferon/ribavirin for chronic genotype 1 HCV infection...
  27. pmc Evaluation of commercially available and in-house reverse transcription-PCR assays for detection of hepatitis G virus or GB virus C
    X Forns
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0740, USA
    J Clin Microbiol 35:2698-702. 1997
    ..In summary, RT-nested PCR and a commercially available RT-PCR assay for HGV or GBV-C gave concordant results for 96% of the patients tested...
  28. doi request reprint Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study
    José A Carrión
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Ciberehd and IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 50:719-28. 2009
    ..Recurrence of hepatitis C after liver transplantation (LT) is universal and may cause premature graft loss. We evaluated the efficacy and safety of antiviral therapy in HCV-infected patients with decompensated cirrhosis awaiting LT...
  29. ncbi request reprint Hepatitis C virus kinetics during and immediately after liver transplantation
    Montserrat Garcia-Retortillo
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, University of Barcelona, Villaroel 170, Barcelona 08036, Catalonia, Spain
    Hepatology 35:680-7. 2002
    ..HCV infection of the graft, however, is an extremely dynamic process and viral replication begins a few hours after LT...
  30. ncbi request reprint [Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]
    Montse Laguno
    Servicio de Enfermedades Infecciosas, Hospital Clínic Universitari de Barcelona IDIBAPS, Universitat de Barcelona, Spain
    Enferm Infecc Microbiol Clin 23:32-40. 2005
    ..Currently, the combination of ribavirine and a new pegilated formulation of the interferon has become the standard in the treatment reaching rates of sustained viral response around 40-80%...
  31. ncbi request reprint Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C
    Francesc Puig-Basagoiti
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina IMD, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    J Gen Virol 86:1067-75. 2005
    ..These observations suggest that the composition and dynamics of HCV NS5A quasispecies, particularly in the V3 domain, may play a role in the response to combined IFN/ribavirin therapy...
  32. doi request reprint Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C
    D C Balderramo
    Liver Unit, Institut Clinic de Malalties Digestives i Metaboliques, Hospital Clinic, Barcelona, Catalonia, Spain
    Dig Liver Dis 41:e4-7. 2009
    ..A pathogenic role of pegylated interferon alpha as a trigger factor for antiphospholipid syndrome development is suggested...
  33. ncbi request reprint Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C
    Eva Martinez-Bauer
    Liver Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Hepatology 43:72-80. 2006
    ..In conclusion, these models predicted response to therapy before or after 4 weeks of treatment in approximately 60% of genotype 1 patients and may be valuable for the management of this condition...
  34. doi request reprint Virology and pathogenesis of hepatitis C virus recurrence
    Santseharay Ramírez
    Liver Unit, Hospital Clinic, Institut d Investigacion Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain
    Liver Transpl 14:S27-35. 2008
    ....
  35. doi request reprint Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation
    José A Carrión
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Barcelona, Spain
    Hepatology 51:23-34. 2010
    ..75 and 0.80, respectively, in the validation group. CONCLUSION: Early and repeated LSM following hepatitis C recurrence in combination with clinical variables discriminates between rapid and slow fibrosers after LT...
  36. ncbi request reprint Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases
    Manuel Ramos-Casals
    Department of Autoimmune Diseases, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, School of Medicine, University of Barcelona, Spain
    Medicine (Baltimore) 82:87-96. 2003
    ..Hemolytic anemia and severe thrombocytopenia were the most frequent cytopenias observed. Most patients responded well to corticosteroids, although a higher rate of mortality was observed in those with liver cirrhosis...
  37. ncbi request reprint Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation
    Montserrat Garcia-Retortillo
    Liver Unit, Hospital Clinic, Institut de Malalties Digestives, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Hepatology 40:699-707. 2004
    ..Although our results were based on a single-center experience, they should be considered in the decision-making process of transplant programs, since severe HCV recurrence may ultimately compromise graft and patient survival...
  38. ncbi request reprint Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation
    Antoni Rimola
    Liver Unit, Hospital Clinic, IDIBAPS, Villaroal 170, 08036 Barcelona, Spain
    Transplantation 78:686-91. 2004
    ....
  39. ncbi request reprint Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases
    Manuel Ramos-Casals
    Department of Autoimmune Diseases, School of Medicine, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, Barcelona, Spain
    Semin Arthritis Rheum 36:189-96. 2006
    ..To analyze the etiology, clinical presentation, and outcomes of patients with life-threatening cryoglobulinemic vasculitis...
  40. ncbi request reprint [Hepatitis C in Spain]
    Miguel Bruguera
    Servicio de Hepatologia, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, Barcelona, Espana
    Med Clin (Barc) 127:113-7. 2006
    ..All efforts to increase the screening of hidden cases of hepatitis C in primary health-care centers, allowing a prompt treatment before an advanced stage, will have a beneficial impact both in economic and social terms...
  41. ncbi request reprint Evolution of hepatitis C virus quasispecies immediately following liver transplantation
    Anna Feliu
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Catalonia, Spain
    Liver Transpl 10:1131-9. 2004
    ..The "bottleneck" effect caused by the implantation of a new graft and the lack of selective pressure due to the strong immunosuppression most likely explain this particular pattern of genetic evolution...
  42. ncbi request reprint Prevention and treatment of hepatitis C virus recurrence after liver transplantation
    Montserrat Garcia-Retortillo
    Liver Unit, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain
    J Hepatol 41:2-10. 2004
  43. ncbi request reprint Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation
    José A Carrión
    Liver Unit, Institut de Malalties Digestives, Centre de Diagnòstic per l Imatge, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Liver Transpl 12:1791-8. 2006
    ..In conclusion, determination of liver stiffness is an extremely valuable tool to assess the severity of HCV recurrence after LT and in reducing the need of follow-up liver biopsies...
  44. doi request reprint Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains
    Santseharay Ramírez
    Liver Unit, IMDiM, Hospital Clinic, CIBERehd, IDIBAPS and University of Barcelona, Barcelona, Spain
    J Gen Virol 91:1183-8. 2010
    ..This would suggest that competition might not be limited to the replication level, but could also take place during virus entry...
  45. ncbi request reprint Performance of hepatitis C virus core antigen immunoassay in monitoring viral load after liver transplantation
    Anna Massaguer
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Transplantation 79:1441-4. 2005
    ..The aim of this study was to compare the performance of HCV-RNA and HCV core antigen determination in a cohort of 116 HCV-infected patients who underwent LTx...
  46. ncbi request reprint Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation
    Alejandro Blasco
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Hepatology 43:492-9. 2006
    ..80), an HVPG of 6 mm Hg or greater was extremely accurate at identifying patients at risk of disease progression (AUC: 0.96). In conclusion, HVPG determination is a valuable tool for follow-up in patients with HCV recurrence after LT...
  47. ncbi request reprint Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome
    Manuel Ramos-Casals
    Department of Autoimmune Diseases and Hepatology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, IDIBAPS, School of Medicine, University of Barcelona, Barcelona, Spain
    J Rheumatol 33:1593-9. 2006
    ..To analyze the prevalence and clinical significance of liver involvement in patients with Sjögren's syndrome (SS), focusing on the characterization and differentiation of autoimmune versus chronic viral liver disease...
  48. pmc Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C
    Jordi Colmenero
    Liver Unit, Institut Clinic de Malalties Digestives i Metaboliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Catalonia, Spain
    Am J Physiol Gastrointest Liver Physiol 297:G726-34. 2009
    ..Controlled studies are warranted to assess the effect of AT1 receptor blockers in chronic liver injury...
  49. ncbi request reprint [Use of complementary and alternative medicine in patients with chronic hepatitis C]
    Miguel Bruguera
    Servicio de Hepatologia, Instituto de Enfermedades Digestivas, Hospital Clinic, and Departamento de Medicina, Facultad de Medicina, Universidad de Barcelona, Spain
    Med Clin (Barc) 122:334-5. 2004
    ..However, their use among patients simultaneously treated by the mainstream medicine is largely unknown. Our goal was to assess how many patients with chronic hepatitis C treated in a tertiary hospital use or have used CAM...
  50. doi request reprint Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans
    Montserrat Moreno
    Liver Unit, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Hepatology 51:974-85. 2010
    ..Conclusion: Ghrelin exerts antifibrotic effects in the liver and may represent a novel antifibrotic therapy...
  51. ncbi request reprint Expected developments in hepatology
    Xavier Forns
    Liver Unit, Hospital Clinic, Institut d Investigaciones Biomèdiques August Pi i Sunyer, University of Barcelona, Spain
    Best Pract Res Clin Gastroenterol 16:957-70. 2002
    ..The risk factors and primary, secondary and tertiary prevention of the condition are also analysed. Finally, the development of new therapeutic strategies for hepatocellular carcinoma is evaluated by evidence-based studies...
  52. ncbi request reprint Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006)
    Didier Samuel
    HepatoBiliary Centre, Inserm Paris XI U 785, Paul Brousse Hospital, APHP, Villejuif, France
    J Hepatol 45:127-43. 2006
  53. ncbi request reprint DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice
    Xiaoying Ma
    Loeb Health Research Institute, 725 Parkdale Avenue, Ottawa, Ont, Canada K1Y 4E9
    Vaccine 20:3263-71. 2002
    ..These results may have implications for the design and development of HCV DNA vaccines...
  54. ncbi request reprint Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061
    Eva Herrmann
    Medizinische Klinik und Poliklinik, Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Antivir Ther 11:371-6. 2006
    ..Estimates of viral clearance and infected-cell loss support conclusions on these rates and on treatment mechanisms from previous studies on interferon-alpha-based treatments...
  55. ncbi request reprint HCV: alive and kicking in living donor liver grafts?
    Xavier Forns
    Hepatology 42:1258-60. 2005
  56. ncbi request reprint Antiviral therapy in HCV decompensated cirrhosis: to treat or not to treat?
    Miquel Navasa
    J Hepatol 46:185-8. 2007
  57. doi request reprint Non-invasive evaluation of liver fibrosis using transient elastography
    Laurent Castera
    Departments of Hepatology, Hospital Saint André and Haut Lévêque, University Hospital of Bordeaux, Avenue Magellan, Pessac, France
    J Hepatol 48:835-47. 2008
    ..Guidelines are needed for the use of TE in clinical practice...
  58. ncbi request reprint Treatment of HCV infection in patients with advanced cirrhosis
    Xavier Forns
    Hepatology 40:498. 2004
  59. ncbi request reprint Hepatitis C virus and human immunodeficiency virus: the un-won battle
    Javier Garcia-Samaniego
    Hepatology 46:611-4. 2007
  60. ncbi request reprint Living donor liver transplantation and hepatitis C: lessons from the learning curve?
    José A Carrión
    Liver Transpl 13:18-20. 2007
  61. ncbi request reprint Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
    Holger Hinrichsen
    Medizinische Universitatsklinik, Kiel, Germany
    Gastroenterology 127:1347-55. 2004
    ..BILN 2061 is a potent and specific inhibitor of HCV serine protease in vitro. Preclinical toxicology data and studies in healthy volunteers supported the administration of BILN 2061 to patients with HCV infection...
  62. ncbi request reprint Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation
    Harel Dahari
    Faculty of Life Sciences, Bar Ilan University, 52900 Ramat Gan, Israel
    J Hepatol 42:491-8. 2005
    ..5-2h) to allow such analysis. Here we mathematically analyze viral decline during liver transplantation beyond the period of the anhepatic phase and examine the possibility of viral compartmentalization...
  63. ncbi request reprint [Current epidemiology of viral hepatitis: who is affected and who can be protected?]
    Miquel Bruguera
    Enferm Infecc Microbiol Clin 22:443-7. 2004
  64. doi request reprint MR elastography to assess liver fibrosis
    José A Carrión
    Radiology 247:591; author reply 591-2. 2008
  65. ncbi request reprint The extrahepatic contribution to HCV plasma viremia
    Harel Dahari
    J Hepatol 45:626-7; author reply 627-8. 2006